The rate of contralateral prophylactic mastectomy has more than doubled in the past decade. 4 This rising trend favoring contralateral prophylactic mastectomy continues despite the absence of a clear survival advantage over unilateral mastectomy. [5] [6] [7] This may be attributable in part to nononcologic benefits, including quality of life from the patient's perspective. Women undergoing contralateral prophylactic mastectomy with immediate breast reconstruction have been reported to have an improvement in breast cancer-related anxiety and satisfaction with their breasts. 8, 9 These intangible benefits may be drivers in the decision for contralateral prophylactic mastectomy. Nevertheless, concerns exist in the oncologic community about this trend. The American Society of Breast Surgeons recently produced a consensus statement advising against contralateral prophylactic mastectomy in average-risk women, in whom the procedure does not provide oncologic benefit. 10 With the notion that contralateral prophylactic mastectomy is potentially unnecessary from an oncologic standpoint in many patients, information on the financial burden of contralateral prophylactic mastectomy on the health care system is needed. Single-institution studies have demonstrated higher short-term health care costs of contralateral prophylactic mastectomy in averagerisk women. 11 In contrast, cost-effectiveness of contralateral prophylactic mastectomy compared with routine surveillance has been demonstrated for average-risk women younger than 70 years. 12 However, little is known about the cost of contralateral prophylactic mastectomy with immediate breast reconstruction on the national level. Thus, the purpose of our study is to evaluate health care resource use with mastectomy and reconstruction in women undergoing unilateral mastectomy and contralateral prophylactic mastectomy using a nationwide database.
PATIENTS AND METHODS

Data Source and Sample
We 13 Encrypted patient identification numbers are used to connect encounters, resource use, pharmacy information, and health plan details. Given the deidentified nature of the data, our study obtained exempt status from the University of Michigan Institutional Review Board.
We included women, age 18 years or older, with diagnosed unilateral breast cancer who underwent mastectomy with immediate breast reconstruction during the study period. We then separated the patients into two groups: patients undergoing unilateral mastectomy with immediate breast reconstruction (unilateral mastectomy) and patients undergoing a unilateral mastectomy with contralateral prophylactic mastectomy and immediate breast reconstruction (contralateral prophylactic mastectomy). We excluded all patients with bilateral synchronous breast cancer, patients with a personal history or family history of breast cancer, patients with a personal history of ovarian cancer, and patients with BRCA1 and BRCA2 genetic mutations. As the intent of the study was to focus on patients with early-stage breast cancer, patients who underwent neoadjuvant chemotherapy and adjuvant radiotherapy were also excluded given that these are typically patients with advanced disease. (See Table, 
Dependent Variable
The cumulative cost of care for the patient groups over an 18-month period after surgery was our outcome variable. The Consumer Price Index from 2015 was used to adjust the cost value. The components of cumulative cost included the cost of the index procedure, secondary procedures, complications, clinic visits, emergency department visits, and hospital readmissions. Index procedure costs comprised the costs of the mastectomy, the associated breast reconstruction, and the hospital stay. For women undergoing unilateral mastectomy, secondary procedures included symmetry procedures for the contralateral breast.
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Adjuvant chemotherapy was also included in the cumulative cost variable. We also calculated the expenditure associated with the individual components of the total cost.
Explanatory Variables
Variables 
Statistical Analysis
The association between women who underwent contralateral prophylactic mastectomy and patient demographic data, health care use, and cost were examined using the chi-square test. We used a log-transformed multivariable linear regression model to investigate the relationship between contralateral prophylactic mastectomy and cost. In the model, we controlled for patient and hospital characteristics. We calculated predicted cost and the corresponding 95 percent confidence interval from the models. The data analysis was generated using SAS 9.4 (SAS Institute, Inc., Cary, N.C.).
RESULTS
During the study period (2009 to 2013), 2343 women met our inclusion criteria and had at least 18 months of continuous enrollment with postoperative data. Our cohort included 1295 women (55 percent) who underwent unilateral mastectomy with reconstruction and 1048 women (45 percent) who underwent unilateral mastectomy with contralateral prophylactic mastectomy and reconstruction (Table 1) . Women choosing contralateral prophylactic mastectomy had higher preoperative risk, as measured by the Elixhauser comorbidity score (p = 0.004). Fewer women who had contralateral prophylactic mastectomy required chemotherapy (24 percent in the contralateral prophylactic mastectomy group versus 33 percent in the unilateral mastectomy group; p < 0.001). There were no differences in the distribution of the type of reconstruction (implant versus autologous) between the study groups.
Overall, complication rates were slightly higher in the contralateral prophylactic mastectomy group both at 30 days and at 18 months postoperatively. However, these differences did not reach statistical significance (Table 2) . Patients undergoing contralateral prophylactic 328 (25) 290 (28) 2 (13-20) 284 (22) 204 (19) 3 (21-27) 281 (22) 178 (17) mastectomy had fewer clinic visits than those who underwent unilateral mastectomy ( Table 3) . Use of the emergency department followed a similar pattern, with 8 percent of women who underwent contralateral prophylactic mastectomy using the emergency department compared with 11 percent of women who underwent unilateral mastectomy (p < 0.001) (Fig. 1) . Postoperative hospital re admission rates did not differ significantly based on surgical intervention. Table 4 outlines the cost of health care use of the two groups. The cost of the index oncologic and reconstructive procedure was significantly higher for the women undergoing contralateral prophylactic mastectomy (contralateral prophylactic mastectomy, $17,095; unilateral mastectomy, $10,628; p < 0.001). Women who underwent contralateral prophylactic mastectomy had a higher cumulative cost within 18 months (contralateral prophylactic mastectomy, $37,811; unilateral mastectomy, $33,557; p < 0.001), with a mean difference in cost between the cohorts of $4254 (Table 4) . Secondary procedures within 18 months of mastectomy and reconstruction were significantly higher in patients undergoing contralateral prophylactic mastectomy (contralateral prophylactic mastectomy, $8317; unilateral mastectomy, $5862; p = <0.001). The cost related to clinic visits was higher after unilateral mastectomy ($1543 versus $1260; p < 0.001). No significant differences in cost were observed for postoperative complications, emergency department visits, or hospital readmissions between the two groups.
After separating the cohorts by reconstruction type, contralateral prophylactic mastectomy was cumulatively more expensive for autologous reconstruction (contralateral prophylactic mastectomy, $68,492; unilateral mastectomy, $49,013; p < 0.001) and for implant-based reconstruction (contralateral prophylactic mastectomy, $32,446; unilateral mastectomy, $31,174; p < 0.001) ( Table 5) . Women who underwent contralateral prophylactic mastectomy with autologous and implant-based breast reconstruction had a more costly index oncologic and reconstruction procedure compared with unilateral mastectomy (p <0.001). However, the cost of secondary procedures for autologous breast reconstruction was similar between contralateral prophylactic mastectomy and unilateral mastectomy (p = 0.248); whereas patients undergoing contralateral prophylactic mastectomy and implant-based reconstruction had significantly higher expenditure for secondary procedures compared with women undergoing unilateral mastectomy and implantbased reconstruction (contralateral prophylactic mastectomy, $8143; unilateral mastectomy, $6010; p < 0.001).
In multivariable analysis, receipt of contralateral prophylactic mastectomy was predictive of higher cost (adjusted mean difference in cumulative cost between contralateral prophylactic mastectomy and unilateral mastectomy, $11,872; 95 percent CI, $8920 to $15,029; p < 0.001) ( Table 6 ). Patients with complications or patients requiring readmission had increased expenditure. However, emergency department visits and number of clinic visits within 18 months were not predictive of increased spending. Increased cost was associated with autologous breast reconstruction (adjusted mean difference in cumulative cost between autologous and implant reconstruction, $37,136; 95 percent CI, $31,016 to 43,853; p < 0.001).
DISCUSSION
Health care costs in the United States are considerable and continue to rise. In 2015, health care expenditure accounted for 17.8 percent of the gross domestic product, in comparison to 17.4 percent in 2014. 16 Given the substantial financial burden of health care in the United States, policymakers are moving toward value-based health care and bundling of payments. Contralateral prophylactic mastectomy represents a surgical procedure that warrants a closer evaluation with a focus on resource use given the controversy that surrounds its widespread application. In this study of nationwide insurance claims data on breast reconstruction patients, we found that contralateral prophylactic mastectomy is significantly more expensive than unilateral mastectomy. The index procedures (mastectomy and reconstruction) and secondary revision of the reconstructive procedures were the largest contributors to the observed differences in cost. Over the 18-month postoperative period, this increased cost for contralateral prophylactic mastectomy persisted despite significantly lower clinic and emergency department use. Value in health care has been defined as outcomes relative to monetary cost. 17 In the current political climate, policy makers advocate for improved value either by reducing cost or improving outcomes. In the field of surgery, outcomes are heterogeneous, intrinsically condition-specific, and move beyond the morbidity and mortality associated with the surgery itself. 18 These outcomes must be assessed at the patient level. 19 For breast reconstruction including contralateral prophylactic mastectomy, outcomes can range from postoperative complications to patient-reported assessments of postoperative well-being. Breast cancer patients choose contralateral prophylactic mastectomy for a variety of reasons. These reasons must be factored into the outcome equation and may trump the lack of survival benefit of contralateral prophylactic mastectomy in low-risk women. Therefore, in the discussion of value of contralateral prophylactic mastectomy, health care policy makers with the help of plastic surgery professional societies, providers, and patients need to deliver quality measures to improve outcomes and subsequently the value of contralateral prophylactic mastectomy. The Medicare Access and CHIP Reauthorization Act was passed in 2015 and pushes the health care system toward a valuebased payment model with the purpose of improving outcomes at a lower cost. [20] [21] [22] Within the Medicare Access and CHIP Reauthorization Act, quality assurance programs were formed to provide performance measures for health care delivery. The American Society of Plastic Surgeons, in compliance with the Medicare Access and CHIP Reauthorization Act, has developed unique quality performance assessments for plastic surgeons. These measure sets evaluate providers on the Plastic and Reconstructive Surgery • May 2018 quality of care they deliver, improvement in clinical practice, resource use, and advancement of care information. 23 They are aimed at minimizing complications, thus improving plastic surgery outcomes. However, as outcomes encompass more than surgical complications, a broader holistic view is essential.
In the absence of an increased risk for future breast cancer, women diagnosed with unilateral breast cancer opt for contralateral prophylactic mastectomy for a variety of reasons. Gaining an understanding of factors that influence women's decisions for contralateral prophylactic mastectomy has been critical in efforts made to better guide patients through these complex decisions, avoid overtreatment, and improve outcomes. Anxiety after treatment is a primary example of an outcome, unrelated to morbidity, that patients find to be important. In a multicenter prospective assessment of patient-reported outcomes in women undergoing contralateral prophylactic mastectomy or unilateral mastectomy with reconstruction, women who underwent contralateral prophylactic mastectomy were found to have higher levels of anxiety before mastectomy. 9 Following mastectomy, the levels of anxiety in these patients who had undergone contralateral prophylactic mastectomy or unilateral mastectomy were similar. 9 Other studies have corroborated this finding, citing anxiety, worry about cancer recurrence, and need for less surveillance as some reasons for decisions in favor of contralateral prophylactic mastectomy. 2, [24] [25] [26] Furthermore, a desire for symmetry with improved breast aesthetics has also been identified as an additional factor impacting decisions for contralateral prophylactic mastectomy. [27] [28] [29] A recent qualitative study on a cohort of reconstruction patients with unilateral early-stage breast cancer found that, although desires for symmetry were not the primary reason for decisions made in favor of contralateral prophylactic mastectomy, they played a supportive role. 2 Patients report improved satisfaction with breasts after contralateral prophylactic mastectomy with bilateral implant reconstruction compared with those who have undergone unilateral mastectomy with similar reconstruction. 9 These nononcologic factors must be factored into the discussion on outcomes and value of contralateral prophylactic mastectomy for breast cancer patients.
A primary concern with widespread use of contralateral prophylactic mastectomy is the potential for increased postoperative morbidity. Studies have reported on higher surgical complication rates of contralateral prophylactic mastectomy compared with unilateral mastectomy. 11 Furthermore, patients undergoing contralateral prophylactic mastectomy were more likely to have breast reconstruction and, as expected, receipt of reconstruction was more costly. Other studies, however, have analyzed the cost-effectiveness of contralateral prophylactic mastectomy in comparison with routine surveillance in the long term. 12, 33 A study by Mattos et al. used a simplified decision tree analysis and determined that contralateral prophylactic mastectomy with reconstruction was cost-effective when the incidence of breast cancer exceeded 0.6 percent per year. 33 Zendejas et al. found that contralateral prophylactic mastectomy was less costly than surveillance for women diagnosed with unilateral breast cancer who were younger than 70 years. 12 However, postmastectomy reconstruction was not part of the cost variable in this study. Although cost-effectiveness is beyond the scope of this study, these findings are logical and highlight the balance that is needed when evaluating the cost of contralateral prophylactic mastectomy to the health care system. This study on the financial implications of contralateral prophylactic mastectomy is just one piece in the discussion of value, and robust outcomes data are needed to justify the increased cost of contralateral prophylactic mastectomy.
This study has a number of limitations. We used data from the Truven MarketScan databases over a 5-year period and were unable to study the longterm cost implications of contralateral prophylactic mastectomy. Furthermore, MarketScan only includes information from commercially insured patients or those with private Medicare supplemental insurance, thus limiting the generalizability of this study to other insurers or the uninsured. Our analyses did not include race or ethnicity, as these data points are unavailable in MarketScan. Race has been shown to have an influence on medical expenditure for breast cancer treatment, including inpatient, outpatient, and medication costs. 34 In using a claims database, there is a lack of granularity regarding clinical characteristics, including family history and adoption status of the patients. Therefore, we could not control for these factors.
CONCLUSIONS
As nationwide rates of contralateral prophylactic mastectomy continue to rise, the cost of contralateral prophylactic mastectomy to the health care system remains a public health predicament. Contralateral prophylactic mastectomy is significantly more expensive for the index oncologic and reconstructive procedure, secondary procedures, and cumulatively within 18 months of surgical treatment. However, monetary cost is only part of the equation in the discussion of value of contralateral prophylactic mastectomy, and all outcomes, including complications and patient-reported outcomes, must be factored into the determination of value for contralateral prophylactic mastectomy.
